Temporal Trends and Antimicrobial Susceptibility Patterns of ESKAPE Pathogens Recovered from Clinical Specimens in Western Oromia, Ethiopia: Implications for AMR Surveillance and Antimicrobial Stewardship

In the quiet corners of hospitals and clinics, a silent struggle plays out between the medicines doctors prescribe and the microscopic invaders they are meant to defeat. For decades, antibiotics have been the reliable shield against bacterial infections, but that shield is slowly developing cracks. A specific group of bacteria, known by the acronym ESKAPE, has earned a notorious reputation for its ability to evade these drugs. These are not just ordinary germs; they are a collection of six distinct types that have learned to survive even the strongest treatments, making them a leading cause of difficult-to-treat infections in healthcare settings around the world. When these bacteria multiply and spread, they can turn routine illnesses into life-threatening conditions, leaving doctors with fewer options to save their patients. Understanding how these bacteria behave, where they hide, and how they change over time is essential for keeping communities safe.

In the western region of Oromia, Ethiopia, a team of researchers at the Nekemte Public Health Research and Referral Laboratory Center decided to take a close look at this growing threat. They wanted to see what was happening right in their own backyard over a three-year period, from 2023 to 2025. Instead of guessing, they went through thousands of records from their laboratory, examining the bacteria that had been grown from patient samples like blood, urine, and wound swabs. Their goal was simple but critical: to track which of these dangerous ESKAPE bacteria were showing up, how often they were appearing, and whether the medicines used to kill them were still working.

The researchers found that these tough bacteria were everywhere. Out of every hundred bacteria they identified in the lab, nearly sixty were part of the ESKAPE group. This means that for a large portion of the patients tested, the infection was caused by one of these hard-to-treat organisms. The most common culprit was a bacterium called Staphylococcus aureus, which made up more than sixty percent of the ESKAPE cases they found. The next most frequent was Klebsiella pneumoniae, followed by a type of bacteria known as Pseudomonas. While the number of these bacteria fluctuated slightly from year to year—peaking in 2024 before dipping slightly in 2025—the overall picture remained consistent: these resistant organisms were a dominant force in the local healthcare system.

What made the situation particularly alarming was not just the presence of these bacteria, but their refusal to die when exposed to antibiotics. The researchers tested the bacteria against a wide range of common drugs and found a disturbing pattern of resistance. For the Staphylococcus aureus bacteria, almost all of them were immune to penicillin, a drug that has been used for decades. In fact, between ninety-five and ninety-nine percent of these isolates could not be killed by it. The situation was similar for the Klebsiella pneumoniae bacteria, which showed high resistance to a class of drugs called cephalosporins, often used as a backup when first-line treatments fail. Even more concerning, the resistance to a powerful drug called meropenem, which is usually reserved for the most severe infections, was rising steadily among Pseudomonas bacteria, climbing from half of the cases in 2023 to over seventy percent by 2025.

The study also revealed that these bacteria were not just surviving; they were becoming masters of resistance. The researchers calculated a score to measure how many different types of antibiotics a single bacterium could resist. They found that more than eighty percent of the ESKAPE bacteria they studied had a high score, meaning they were resistant to multiple drugs at once. This is known as multidrug resistance. When a bacterium becomes resistant to three or more different classes of antibiotics, it leaves doctors with very few, if any, effective treatments. The data showed that this high level of resistance was found in patients of all ages, from young children to the elderly, and in both hospital settings and outpatient clinics. However, the bacteria were slightly more common in patients who were already hospitalized, likely because hospitals are places where these tough germs circulate more freely and where patients are exposed to more antibiotics.

The researchers also looked at where these infections were coming from. They found that the type of sample mattered. Ear discharge was the most common source of these bacteria, followed by blood and urine. This suggests that infections in the ear, which can be chronic or recurrent, might be a significant reservoir for these resistant strains. The study highlighted that the problem was not limited to one specific hospital or clinic but was a widespread issue across the region, affecting different types of healthcare facilities.

The findings from Nekemte paint a clear picture of a public health challenge that requires immediate attention. The high prevalence of these resistant bacteria, combined with their ability to shrug off multiple drugs, signals that the current ways of managing infections need to change. The researchers concluded that simply relying on standard treatments is no longer enough. To protect patients, healthcare workers need to be more careful about when and how they use antibiotics, ensuring that these powerful drugs are only given when truly necessary. They also emphasized the need for better infection control measures to stop these bacteria from spreading from patient to patient. Most importantly, the study showed that keeping a close watch on these germs is vital. By continuously monitoring which bacteria are present and which drugs still work, doctors can make smarter choices about treatment, potentially saving lives in a world where the old rules of medicine are no longer enough.